- Location
hemophilia
"-
Researchers Have Color-Coded Cells in Female Mice to Display Silenced
Jan 13, 2014Producing brightly speckled red and green snapshots of many different tissues, Johns Hopkins researchers have color-coded cells in female mice to display which of their two X chromosomes has been made inactive, or “silenced.” ...
Tags: X chromosomes, Johns Hopkins, color-coded cells, genetic diversity
-
Ten Transgenic Piglets Have Been Born This Year in Guangdong Province
Dec 25, 2013Along with red, green is the color of this holiday season. And bright green is showing up in more than just decorations. ?In Guangdong Province in Southern China, ten transgenic piglets have been born this year, six of them since August, ...
Tags: Consumer Electronics, Electronics
-
Baxter Today Announced Completion of CE Marking in Europe for The VIVIA HD System
Dec 23, 2013Baxter International Inc. (NYSE:BAX) today announced completion of CE marking in Europe for the VIVIA hemodialysis (HD) system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High ...
-
Baxter International Submitted a BLA to FDA for Approval of 'OBI-1'
Dec 12, 2013Baxter International has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) for the approval of a recombinant antihemophilic porcine sequence factor VIII called 'OBI-1' for the treatment of patients ...
-
Baxter International Has Filed an Application to The US Food and Drug Administration
Dec 11, 2013Baxter International has filed an application to the US Food and Drug Administration (FDA) for a pediatric indication for Rixubis [Coagulation Factor IX (Recombinant)] to treat hemophilia B. The submission was based on a Phase II/III ...
-
FDA Extended Its Review of a Marketing Application for Fusion Protein Alprolix
Dec 5, 2013Biogen Idec announced that the US Food and Drug Administration (FDA) has extended its review of a marketing application for the long-lasting recombinant factor IX Fc fusion protein Alprolix for haemophilia B by three months. The company ...
-
Baxter Has Submitted a Marketing Authorization Application to The EMA
Nov 4, 2013Baxter has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for approval of Rixubis, recombinant factor IX for the treatment and prophylaxis of bleeding in patients of all ages with hemophilia B. ...
Tags: Baxter, European Medicines Agency
-
A Gene Therapy Company Focused on Developing Novel Treatments for Rare Diseases
Nov 4, 2013Fidelity Biosciences, a subsidiary of Fidelity Investments, and US-based Regenx Biosciences have announced the formation of Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases. Dimension ...
Tags: Biosciences, Health, Medicine
-
Inherited Diseases Are The Passing of Bad Characteristics From Generation to Generation
Sep 10, 2013A disease, by definition, is a disorder of structure or function in an organism that produces specific symptoms or signs to indicate its presence. Inheritance, in terms of biology, is the passing of characteristics, good or bad, from ...
Tags: Inherited Blood Diseases, Health, Medicine
-
Alnylam Pharmaceuticals Has Obtained Additional Orphan Drug Designation
Aug 22, 2013RNAi therapeutics company Alnylam Pharmaceuticals has obtained additional orphan drug designation from US FDA for a RNAi therapeutic, ALN-AT3, to treat hemophilia A. With the additional approval, orphan drug designation for GalNAc ...
Tags: Alnylam, Orphan Drug
-
Biogen Idec Is Seeking Marketing Approval From The US FDA
Mar 14, 2013Biogen Idec is seeking marketing approval from the US Food and Drug Administration (FDA) for recombinant factor VIII Fc fusion protein (rFVIIIFc) therapy to treat hemophilia A. The company has submitted a biologics license application ...
Tags: Biogen Idec, FDA, hemophilia A
-
FDA Has Accepted Biogen Idec's Biologics License Application for The Marketing Approval
Mar 6, 2013The US Food and Drug Administration (FDA) has accepted Biogen Idec's biologics license application (BLA) for the marketing approval of recombinant factor IX Fc fusion protein (rFIXFc) for the treatment of hemophilia B. Using the company's ...
Tags: FDA, Idec BLA, hemophilia B
-
Baxter Has Submitted a BLA to The US FDA
Feb 28, 2013Baxter has submitted a biologics license application (BLA) supplement to the US Food and Drug Administration (FDA) for the approval of its prophylaxis treatment of FEIBA NF [Anti-Inhibitor Coagulant Complex], Nanofiltered and Vapor Heated, ...
Tags: Baxter, Feiba NF Drug, Medicine
-
Novo Nordisk Announced The Introduction of HemaGo
Jan 14, 2013Novo Nordisk announced today the introduction of HemaGo, a mobile application (app) to help individuals with hemophilia and their caregivers monitor the details of treatment, including medications, dosing, bleed information and the impact ...
Tags: Novo Nordisk, HemaGo, mobile application, hemophilia, treatment
-
The Drug Candidate Is Being Studied to Treat Acquired Hemophilia a Individuals
Dec 14, 2012Ipsen and Inspiration Biopharmaceuticals have announced FDA Fast Track status to an intravenous recombinant porcine factor VIII, OBI-1, for acquired hemophilia A therapy. The drug candidate is being studied to treat acquired hemophilia A ...
Tags: FDA, fast track status, drug candidate
